Abstract
Since the first description of self-reactive antibodies in systemic autoimmune rheumatic diseases, many autoantigens have been identified as useful diagnostic biomarkers in clinical immunology. Among the autoantigens, double-stranded desoxoribonucleic acid (dsDNA), the Smith antigen (Sm), topoisomerase-I (topo-I), proliferating cell nuclear antigen (PCNA), and others were described as hallmark targets of systemic autoimmune diseases. The detection of the corresponding autoantibodies can be performed with a variety of immunoassays based on native antigens, recombinant proteins or synthetic peptides. As discussed in this review, synthetic peptides often represent highly accurate antigenic ligands for autoantibody assays that can be easily produced in high quality and quantity and with remarkable reproducibility. Furthermore, the use of peptides that focus on abrogation or neutralization of pathogenic autoantibodies provides a possible new therapeutic approach to the management of autoimmune disorders. There is an increasing number of interesting examples for the application of synthetic peptides in diagnostic approaches. Todays sophisticated epitope mapping methods will potentate the identification of further peptides that can be possibly used as specific targets in diagnostic and therapeutic approaches to improve the patients treatment. This may lead to a new scientific research area with high impact on the development of diagnostic and therapeutic products, to the area of peptide engineering and “theranostics”.
Keywords: Peptide, autoantibody, SLE, dsDNA, Systemic rheumatic disease
Current Medicinal Chemistry
Title: Synthetic Peptides: The Future of Patient Management in Systemic Rheumatic Diseases?
Volume: 14 Issue: 26
Author(s): Kai Kessenbrock, Reinout Raijmakers, Marvin J. Fritzler and Michael Mahler
Affiliation:
Keywords: Peptide, autoantibody, SLE, dsDNA, Systemic rheumatic disease
Abstract: Since the first description of self-reactive antibodies in systemic autoimmune rheumatic diseases, many autoantigens have been identified as useful diagnostic biomarkers in clinical immunology. Among the autoantigens, double-stranded desoxoribonucleic acid (dsDNA), the Smith antigen (Sm), topoisomerase-I (topo-I), proliferating cell nuclear antigen (PCNA), and others were described as hallmark targets of systemic autoimmune diseases. The detection of the corresponding autoantibodies can be performed with a variety of immunoassays based on native antigens, recombinant proteins or synthetic peptides. As discussed in this review, synthetic peptides often represent highly accurate antigenic ligands for autoantibody assays that can be easily produced in high quality and quantity and with remarkable reproducibility. Furthermore, the use of peptides that focus on abrogation or neutralization of pathogenic autoantibodies provides a possible new therapeutic approach to the management of autoimmune disorders. There is an increasing number of interesting examples for the application of synthetic peptides in diagnostic approaches. Todays sophisticated epitope mapping methods will potentate the identification of further peptides that can be possibly used as specific targets in diagnostic and therapeutic approaches to improve the patients treatment. This may lead to a new scientific research area with high impact on the development of diagnostic and therapeutic products, to the area of peptide engineering and “theranostics”.
Export Options
About this article
Cite this article as:
Kessenbrock Kai, Raijmakers Reinout, Fritzler J. Marvin and Mahler Michael, Synthetic Peptides: The Future of Patient Management in Systemic Rheumatic Diseases?, Current Medicinal Chemistry 2007; 14 (26) . https://dx.doi.org/10.2174/092986707782360150
DOI https://dx.doi.org/10.2174/092986707782360150 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural and Induced Regulatory T Cells: Targets for Immunotherapy of Autoimmune Disease and Allergy
Inflammation & Allergy - Drug Targets (Discontinued) Vitamin D : Autoimmunity and Gender
Current Medicinal Chemistry Thrombotic Microangiopathies: Towards a Pathophysiology-Based Classification
Cardiovascular & Hematological Disorders-Drug Targets Animal Models of Lupus and Lupus Nephritis
Current Pharmaceutical Design Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors
Current Medicinal Chemistry Invariant Natural Killer T Cell-Based Therapy of Autoimmune Diseases
Current Immunology Reviews (Discontinued) Use of Liposomal Drugs in the Treatment of Rheumatoid Arthritis
Current Rheumatology Reviews Antibody Penetration Into Living Cells: Pathogenic, Preventive and Immuno-Therapeutic Implications
Current Pharmaceutical Design Low 25 Hydroxyvitamin D Levels are Independently Associated with Autoimmune Thyroiditis in a Cohort of Apparently Healthy Overweight and Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Antibodies in HIV Treatment - Classical Approaches to Novel Advances
Current Pharmaceutical Design Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis
Current Pharmaceutical Design Needle-free Gene Delivery Through the Skin: An Overview of Recent Strategies
Current Pharmaceutical Design Selective Binding BAFF/APRIL by the In and Outside Conservative Region of BCMA
Protein & Peptide Letters Animal Models of Central Nervous System Immune-Mediated Diseases: Therapeutic Interventions with Bioactive Peptides and Mimetics
Current Medicinal Chemistry Identification of Expressed miRNAs in Human Rheumatoid Arthritis Using Computational Approach – Discovery of a New miR-7167 from Human
MicroRNA Interactions of Sex Steroids with Mechanisms of Inflammation
Current Drug Targets - Inflammation & Allergy Regulation of B-Cell Activation by Complement Receptors CD21 and CD35
Current Pharmaceutical Design Involvement of IL-1R/TLR Signalling in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Molecular Medicine Treatment of Refractory Autoimmune Diseases with Ablative Immunotherapy Using Monoclonal Antibodies and / or High Dose Chemotherapy with Hematopoietic Stem Cell Support
Current Pharmaceutical Design Gene Therapy Using IL-12 Family Members in Infection, Auto-Immunity, and Cancer
Current Gene Therapy